Independent biopharmaceutical company Specialised Therapeutics (ST) welcomes the approval of ZEPZELCA® (lurbinectedin), in combination with atezolizumab (Tecentriq®), as a new first-line maintenance ...

Boehringer Ingelheim and Zai Lab launch a clinical collaboration to evaluate a dual DLL3‑targeting combination therapy in small cell lung cancer ...

Zai Lab Limited (NASDAQ: ZLAB; HKEX: 9688) today announced clinical data indicating zocilurtatug pelitecan (zoci, formerly ZL-1310), a DLL3-targeting antibody-drug conjugate (ADC), provides rapid and ...

Zai Lab will supply zoci while Boehringer Ingelheim will manage operations, with both companies retaining rights to their ...

Transcription factors, especially FOXP1, are crucial in SCLC chemoresistance, influencing drug sensitivity and resistance pathways. FOXP1 regulates SP8 expression via its super-enhancer, impacting the ...

Credit: Amgen. The application is supported by data from the phase 2 DeLLphi-301 trial. Results showed 40% of patients responded to treatment with Imdelltra. The Food and Drug Administration (FDA) has ...

SCLC, addressing a high-relapse setting with limited second-line efficacy and modest survival benefit. Ifinatamab deruxtecan ...

This antibody-drug conjugate targets a specific protein associated with poor prognosis in patients whose disease progressed after platinum-based chemotherapy.

Overall survival with serplulimab, a novel PD-1 inhibitor being developed in China for extensive-stage small cell lung cancer (ES-SCLC), appears better than that seen with two immune checkpoint ...

Lung cancer is the leading cause of cancer deaths among both men and women. Small-cell lung cancer (SCLC) and non-small-cell lung cancer (NSCLC) are the two main types of lung cancer. Most lung ...

WASHINGTON — Timing matters when it comes to combining immunotherapy with chemoradiation in limited-stage small cell lung cancer (SCLC), according to the phase 3 NRG-LU005 trial presented at the ...